Delivery Order SPE2DB20D3103-SPE2DB22FL5B6
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $15,016.89 for the supply of 4558367829 - ABILIFY 30 MG TABLET 30S. The contract was awarded by the Defense Logistics Agency (DLA), a component of the Department of Defense, and has an ultimate completion date of September 8, 2022. The award is not designated with a set-aside and was made through full and open competition. Amerisourcebergen Drug Corp is a major...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,382.47 Firm Fixed Price Delivery Order contract is for the supply of ABILIFY MAINTENA ER 300 MG VLS, a specialty medication. The contract has an ultimate completion date of January 29, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp Corporate Office Division, a major pharmaceutical distributor. The $10,608.25 firm-fixed-price delivery order is for the supply of ABILIFY MAINTENA ER 400 MG VLS medication. The delivery order has an ultimate completion date of August 15, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,568.80, is for the supply of ABILIFY MAINTENA ER 400 MG VLS, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of January 9, 2024. Amerisourcebergen holds a significant Indefinite Delivery...
- This federal contract award, with ID SPE2DB22D6029|SPE2DB25FLUJE, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,843.01 firm fixed-price delivery order is for the pharmaceutical product ABILIFY MAINTENA ER 400 MG VLS. The contract has an ultimate completion date of March 4, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,842.17 firm fixed-price delivery order is for the supply of ABILIFY MAINTENA ER 400 MG SYRS, a pharmaceutical product. The contract has an ultimate completion date of February 6, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $7,319.20 firm fixed-price delivery order is for the supply of 150 ml bottles of Aripiprazole 1 mg/ml solution. The contract has an ultimate completion date of May 22, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,955.85 Firm Fixed Price Delivery Order is for the supply of 4562252756 ABILIFY MAINTENA ER 400 MG SYRS, with a completion date of September 21, 2023. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,385.56 fixed-price delivery order is for the supply of 4,563,061,270 units of aripiprazole 15 mg tablets. The contract has an ultimate completion date of December 12, 2023. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, running through...
- This federal contract award, with ID SPE2DB22D7058|SPE2DB25FSUR1, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,124.70 Firm Fixed Price Delivery Order is for the provision of 4567142498 - ABILIFY 30 MG TABLET 30S, with a final completion date of February 5, 2025. Amerisourcebergen, a for-profit organization, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB22FL5B6Delivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $6,432.54 for the supply of ABILIFY 2 MG TABLET 30S. The contract was awarded on October 29, 2021 by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of November 1, 2021. The contract is a firm fixed-price delivery order with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that runs through November 2026. This IDC serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military healthcare programs globally. Amerisourcebergen also has a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024 for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.4k | 10/29/21 |